AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 4
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Intravenous 5
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Subcutaneous 1
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB7665 Subcutaneous 2
Description: * Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion
Study NCT02220153 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Placebo
Description: * Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion
Study NCT02233647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
Study NCT01652612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: 8 cmH2O PEEP throughout the period of OLV and 2nd TLV
Study NCT00755092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doula
Description: Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
Study NCT00755092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doula
Description: Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
Study NCT02817256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins and Minerals
Description: Multivitamins and Minerals supplementation
Study NCT04579250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF0103-00-VP (H10ssF-6473)
Description: The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
Study NCT01356264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multimodal prehabilitation
Description: multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
Study NCT02307604 — intervention group
Intervention type: GENETIC
Intervention: Tumour markers testing
Study NCT03458403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motions during gastroscopy
Description: Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
Study NCT00487994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
Study NCT02068664 — intervention group
Intervention type: BEHAVIORAL
Intervention: prism adaptation treatment
Description: Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
Study NCT03934411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: The subjects will orally ingest 100 mg tramadol retard actavis
Study NCT03934411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will orally ingest 100 mg calcium powder
Study NCT02819050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Nasal Continuous Positive Airway Pressure
Study NCT02819050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCPAP
Description: Nasal Continuous Positive Airway Pressure
Study NCT02169700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic compression. Dry Needling
Description: Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
Study NCT02169700 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic compression. Dry Needling
Description: Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
Study NCT02684617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
Study NCT02567916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresofol
Study NCT02567916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02258698 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
Study NCT04342897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3127804
Description: Administered IV
Study NCT00487994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Study NCT00487994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Study NCT04342897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01699204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
Study NCT01699204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel exhaust
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
Study NCT01699204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel exhaust
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
Study NCT01699204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered air
Description: A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
Study NCT02684617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinaciclib
Description: dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
Study NCT03322878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study NCT03322878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study NCT00090779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/ tenofovir disoproxil fumarate
Description: once daily
Study NCT03322878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium SO4
Description: The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
Study NCT00691418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
Study NCT00691418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once per day starting at 22-24 weeks gestation until delivery.
Study NCT04166175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: botox injection in intersphincteric space
Description: injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
Study NCT00090779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: twice daily
Study NCT02651376 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional plus AAIT
Description: Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
Study NCT01165463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT basic training
Description: 10 hours of basic training
Study NCT04078958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon fishmeal
Description: Salmon fishmeal with high protein content
Study NCT01165463 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crossword Puzzles
Description: Subjects train with puzzles 10 hrs in lab.
Study NCT01165463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT booster training
Description: 4 hours of subsequent booster-training
Study NCT00777257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
Description: Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
Study NCT00777257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
Description: Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
Study NCT04078958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey
Description: Whey with high protein content
Study NCT04166175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy
Description: lateral internal sphincterotomy under GA in lithotomy position
Study NCT00795106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Study NCT00777257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Description: Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
Study NCT00795106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Study NCT03565744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B'N Fit POWER
Description: Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
Study NCT02342691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLXA4
Description: BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
Study NCT02342691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral rinse
Description: The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
Study NCT00738595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 302
Description: EVT 302 5 mg once daily
Study NCT00738595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EVT 302, 5 mg
Study NCT00738595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 302 plus open label Nicotine replacement
Description: Double-blind EVT 302 plus open label nicotine replacement
Study NCT00738595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus open label Nicotine Replacement
Description: Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
Study NCT02108470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental consultation using OHIP
Description: The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
Study NCT01378949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5% with adrenaline 5 mcg/cc
Study NCT01378949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 1 mg/cc
Study NCT04360915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067
Description: Take ASK120067 tablets orally in first day at 160 mg in fast condition.
Study NCT04360915 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ASK120067 in fed condition
Description: Take ASK120067 tablets orally in first day at 160 mg in fed condition.
Study NCT05609006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy, Low-Volume ONS
Description: 2 bottles/day of a High-Energy, Low-Volume ONS
Study NCT05609006 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy Standard ONS
Description: 2 bottles/day of a High-Energy Standard ONS
Study NCT03640130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-contingent text enhancement
Description: In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight.
Study NCT06393270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified US Public Health Service (USPHS) criteria
Description: Dental caries classification system
Study NCT03689478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermic intravesical chemotherapy
Description: Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
Study NCT01050868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Combo Kit mg DE/de
Study NCT03383198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine right injection
Description: Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
Study NCT03383198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine left injection
Description: Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
Study NCT02498184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT02498184 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Study NCT01488929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619
Study NCT01488929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00666029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 40 m.g. o.d. tablets for 6 months
Study NCT00666029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT01818921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: ZGN-440 sterile diluent/placebo
Study NCT01818921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2 mg ZGN-440 for injectable suspension
Description: 1.2 mg beloranib